Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New moisturizer study seeks to understand eczema patients on strong medications

NCT ID NCT07577921

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how adults with moderate-to-severe atopic dermatitis (eczema) that is controlled by systemic treatments (like pills or injections) use and feel about a cosmetic moisturizer called RV4427C WM0071. The goal was to understand their needs, expectations, and how satisfied they were with the product. 80 participants completed questionnaires over about a month to share their experiences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

May 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be enrolled from the investigator's outpatients reception and/or from the database of the centre. The subjects corresponding to eligibility criteria may receive a phone call, a letter or an e-mail proposing to participate to the clinical study.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Criteria related to the population: * Subject aged between 18 and 75 years included * Subject having signed his/her written informed consent for his/her participation in the study * Subject affiliated to a social security system or health insurance, or is a beneficiary (if required by national regulations * Subject with appropriate hardware (smartphone and/or tablet and/or computer) to complete digital questionnaires * Subject with a mailbox and internet access to create his account to complete digital questionnaires Criteria related to the disease and treatment: • Subject with moderate to severe AD controlled by systemic treatment, meaning: * Using systemic treatment for AD (biologics, janus kinase inhibitors or conventional immunosuppressants) initiated for at least 6 months at the time of the inclusion visit * With an unchanged systemic treatment dose for at least 2 months at the time of the inclusion visit, * And with an vIGA-ADTM ≤ 2 (Mild). Non Inclusion criteria: Criteria related to the population: * Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his/her consent in writing and to report required information in writing in the questionnaire * For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study * Subject who has forfeited his/her freedom by administrative or legal award or is under guardianship * Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements * Subject who is currently participating, who plans to participate or who has participated within the previous weeks or months in another clinical study liable to interfere with the study assessments according to the investigator's assessment * Subject who has already participated to ADNEEDS study * Subject is in a position likely to represent a conflict of interest and/or is a family member of any people involved in the conduct of the study (secretary, nurse, technician,…), of the investigational site Criteria related to the diseases / skin condition: * Subject with history of allergy or intolerance to any of the tested product ingredients * Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Allergologie et Immunologie Clinique, CHU Lyon Sud

    Pierre-Bénite, F-69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.